Physician profile
James Mitchell Costner
NPI 1841257540
$2,030.71
in general payments reported to CMS, 2019-2025
17 companies · $786 in 2025
The $786 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2021: $68.62 · 2022: $200 · 2023: $296 · 2024: $204 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.20 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $622.31 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $262.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $201.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $159.99 | 2019-2023 | |
| Novo Nordisk INC | $120.25 | 2024-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.37 | 2025 | Jardiance |
| Amgen INC. | $99.66 | 2023 | Repatha |
| Pfizer INC. | $83.47 | 2019-2025 | |
| Axsome Therapeutics, INC. | $81.02 | 2025 | Auvelity, Symbravo |
| Phathom Pharmaceuticals, INC. | $71.54 | 2024-2025 | Voquezna |
| Abbvie INC. | $51.56 | 2024-2025 | |
| Exact Sciences Corporation | $36.95 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $35.78 | 2025 | Watchman Flx |
| Lilly USA, LLC | $32.96 | 2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $17.84 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $17.63 | 2025 | Zoryve |
| Tolmar, INC. | $16.35 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Costner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.